Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. OSTX
stocks logo

OSTX

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax
Wall Street analysts forecast OSTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OSTX is 11.50 USD with a low forecast of 6.00 USD and a high forecast of 17.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast OSTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OSTX is 11.50 USD with a low forecast of 6.00 USD and a high forecast of 17.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.820
sliders
Low
6.00
Averages
11.50
High
17.00
Current: 1.820
sliders
Low
6.00
Averages
11.50
High
17.00
Lake Street
Chad Messer
Buy
downgrade
$18 -> $17
2025-11-18
Reason
Lake Street
Chad Messer
Price Target
$18 -> $17
2025-11-18
downgrade
Buy
Reason
Lake Street analyst Chad Messer lowered the firm's price target on OS Therapies to $17 from $18 and keeps a Buy rating on the shares. The firm, which notes that the company incurred some significant one-time regulatory expenses during the quarter, forecasts a substantially reduced burn for Q4 and into 2026.
D. Boral Capital
Jason Kolbert
Strong Buy
Maintains
$20
2025-04-22
Reason
D. Boral Capital
Jason Kolbert
Price Target
$20
2025-04-22
Maintains
Strong Buy
Reason
D. Boral Capital
Jason Kolbert
Strong Buy
Maintains
$20
2025-04-07
Reason
D. Boral Capital
Jason Kolbert
Price Target
$20
2025-04-07
Maintains
Strong Buy
Reason
Lake Street
Chad Messer
Strong Buy
Initiates
$19
2025-04-02
Reason
Lake Street
Chad Messer
Price Target
$19
2025-04-02
Initiates
Strong Buy
Reason
Lake Street analyst Chad Messer initiated coverage of OS Therapies with a Buy rating and $19 price target. Top line data from a Phase 2b trial of OST-HER2 in recurrent osteosarcoma supports filing for accelerated approval this year, says the analyst, who forecasts the drug could reach market around year-end and sees a $400M peak U.S. market opportunity.
D. Boral Capital
Jason Kolbert
Strong Buy
Maintains
$20
2025-03-31
Reason
D. Boral Capital
Jason Kolbert
Price Target
$20
2025-03-31
Maintains
Strong Buy
Reason
D. Boral Capital
Jason Kolbert
Strong Buy
Maintains
$20
2025-02-24
Reason
D. Boral Capital
Jason Kolbert
Price Target
$20
2025-02-24
Maintains
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for OS Therapies Inc (OSTX.A) is -3.43, compared to its 5-year average forward P/E of -5.71. For a more detailed relative valuation and DCF analysis to assess OS Therapies Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-5.71
Current PE
-3.43
Overvalued PE
-0.80
Undervalued PE
-10.62

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
7.24
Current PS
0.00
Overvalued PS
21.28
Undervalued PS
-6.80
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders areSelling! The selling amount has increased 100.96% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areSelling! The selling amount has increased 100.96% over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

OSTX News & Events

Events Timeline

(ET)
2025-07-03
07:54:11
OS Therapies granted End of Phase 2 Meeting by FDA to review OST-HER2 program
select
2025-06-30 (ET)
2025-06-30
06:04:41
OS Therapies reports 'positive' results from Phase 2b trial of OST-HER2
select
2025-06-24 (ET)
2025-06-24
07:50:52
OS Therapies receives feedback from FDA Type D Meeting for OST-HER2 trial
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
11-22Yahoo Finance
Stonegate Capital Partners Revises Coverage for OS Therapies Inc. (OSTX) in Q3 2025

  • Clinical Milestones: OS Therapies Inc. reported a 75% two-year overall survival (OS) rate for its OST-HER2 treatment in a Phase 2b trial, significantly outperforming historical controls at 40%.

  • Regulatory Progress: The company is on track for U.S. and U.K. regulatory filings, with submissions to the FDA and UK MHRA expected by early 2026, supported by positive trial results.

  • Spinoff Announcement: OS Therapies plans to spin off its OS Animal Health division into a standalone public company in the first half of 2026, allowing shareholders to receive direct equity in the new entity.

  • Financial Overview: The company ended the quarter with approximately $1.9 million in cash and a net loss of $6.9 million, but secured $7.8 million in warrant proceeds post-quarter, extending its financial runway into late 2026.

[object Object]
Preview
4.0
11-21Benzinga
D. Boral Capital Reiterates Buy Rating on OS Therapies with $20 Price Target Intact

  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.

  • Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters for its users.

  • Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, enhancing their trading strategies.

  • Market Winning Tools: Benzinga Pro is designed to help traders win in the markets every day with accurate stock market intelligence.

[object Object]
Preview
2.0
11-17Benzinga
Quantum Computing Stocks Surge Over 23%; Check Out 20 Premarket Movers

  • Quantum Computing Inc. Performance: Quantum Computing Inc. shares surged 23.5% in pre-market trading after reporting better-than-expected Q3 earnings of 1 cent per share, compared to a projected loss of 6 cents, and sales of $384,000, exceeding expectations of $116,667.

  • Other Notable Gainers: WeShop Holdings Limited saw a dramatic increase of 98.6% to $60.00, while MSP Recovery, Genius Group, and Repare Therapeutics also experienced significant gains in pre-market trading.

  • Major Losers: Taitron Components Incorporated fell 39.5% to $1.27 after announcing a quarterly loss and voluntary delisting, while Sonder Holdings Inc. declined 28.6% following a Chapter 7 bankruptcy filing.

  • Market Overview: The pre-market trading session showed a mix of gains and losses among various stocks, with notable fluctuations in share prices following recent earnings reports and corporate announcements.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is OS Therapies Inc (OSTX) stock price today?

The current price of OSTX is 1.82 USD — it has increased 4 % in the last trading day.

arrow icon

What is OS Therapies Inc (OSTX)'s business?

OS Therapies Incorporated is a clinical-stage oncology company focused on the identification, development, and commercialization of new class immunotherapy candidates for solid tumors, beginning with osteosarcoma and other solid tumors. Its pipeline includes two drug technologies: OST-HER2 and OST-tADC. Its lead asset, OST-HER2, is an off-the-shelf immunotherapy, which is a type of cancer treatment that helps one’s immune system fight cancer, comprised of a genetically weakened and modified strain of Listeria monocytogenes, a species of bacteria that causes the infection listeriosis, that expresses HER2 peptides. OST-tADC is a tunable ADC with a plug-and-play platform that features tunable pH-sensitive silicone linkers (SiLinkers). Its clinical-stage cancer immunotherapy programs also include OST-AXAL for human papilloma virus (HPV)-associated cancers; OST-503 for non-small cell lung cancer (NSCLC) & glioblastoma; and OST-PSA for prostate cancer.

arrow icon

What is the price predicton of OSTX Stock?

Wall Street analysts forecast OSTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OSTX is 11.50 USD with a low forecast of 6.00 USD and a high forecast of 17.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is OS Therapies Inc (OSTX)'s revenue for the last quarter?

OS Therapies Inc revenue for the last quarter amounts to -6.88M USD, increased 182.25 % YoY.

arrow icon

What is OS Therapies Inc (OSTX)'s earnings per share (EPS) for the last quarter?

OS Therapies Inc. EPS for the last quarter amounts to -4706192.00 USD, increased 39.04 % YoY.

arrow icon

What changes have occurred in the market's expectations for OS Therapies Inc (OSTX)'s fundamentals?

The market is revising No Change the revenue expectations for OS Therapies Incorporated (OSTX) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -17.27%.
arrow icon

How many employees does OS Therapies Inc (OSTX). have?

OS Therapies Inc (OSTX) has 4 emplpoyees as of December 05 2025.

arrow icon

What is OS Therapies Inc (OSTX) market cap?

Today OSTX has the market capitalization of 63.91M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free